ÕÒÂÛÎÄÍø > ҽҩѧÂÛÎÄ > ҽѧÂÛÎÄ >

¿¹ÏËÁé¿ÅÁ£¶ÔÂýÐÔÉö˥ҩЧѧ¶¯ÎïʵÑéÑо¿(1)

            ×÷Õß:ºîÎÀ¹ú£¬ÍÀÁ¢Èº£¬ºÎÁ¢Èº£¬¸ß½¨¶«

¡¾ÕªÒª¡¿  Ä¿µÄ  ¹Û²ìÖÐÒ©¿¹ÏËÁé¿ÅÁ£¶Ô´óÊóÊÔÑéÐÔÂýÐÔÉöË¥µÄҩЧ×÷Óã¬Ì½ÌÖ´Ë·½¸ÄÉÆÉöСÇòÓ²»¯¡¢Éö¼äÖÊÏËά»¯µÄ»úÖÆ¡£ ·½·¨   ÉèÁ¢¶ÔÕÕ×顢ģÐÍ×é¡¢¿¹ÏËÁé×é¡¢´ó»Æ×é¡¢µ¤²Î×é¹²5×é¡£·þÒ©30Ìì¡£²ÉÓÃspss ·ÖÎö £¬Ñª¼¡ôû£¨scr£©¡¢ÑªÄòËØµª£¨bun£©ÓÃÒ© ÖÎÁÆ Ç°ºóÖ¸±ê¼°µ¨¹Ì´¼£¨chl£©¡¢¸ÊÓÍÈýõ¥£¨tg£©£¬¸÷×é¼äÖ¸±êµÄ±ä»¯ºÍ½øÐÐÉöÔà×éÖ¯ÐÎ̬ѧ¹Û²ì¡£½á¹û  Ä£ÐÍÓ뿹ÏËÁé×é±È½Ï£ºscr¡¢bunÖ¸±êÃ÷ÏÔ½µµÍ£¨p<0.05£©£¬¸÷ÖÎÁÆ×é¼äµÄ±È½Ï£º¿¹ÏËÁé×éscr¡¢bunÖ¸±ê¾ùµÍÓÚµ¤²Î×éºÍ´ó»Æ×é¡£tg¿¹ÏËÁé×éÓëÄ£ÐÍ×é±È½Ï£¬p<0.05¡£Éö×éÖ¯ÐÎ̬¿É¼û£º¿¹ÏËÁé×éÉöË¥´óÊóÉöСÇòήËõÃ÷ÏÔ¼õÇᣬ»ú¹¹½Ï½Ó½üÕý³£¡£½áÂÛ  ¿¹ÏËÁé¿ÅÁ£¶Ô¸ÄÉÆÊÔÑéÐÔÂýÐÔÉöË¥ÓнÏÃ÷ÏÔµÄҩЧ×÷Óá£
   
    ¡¾¹Ø¼ü´Ê¡¿  ¿¹ÏËÁé¿ÅÁ££» ¶¯ÎïʵÑ飻 ÂýÐÔÉöÑ×£» Éö¼äÖÊÏËά»¯
   
    research about animal experiment of kang xian ling ke li (kxlkl) on chronic renal failure in pharmacodynamics 
    
    ¡¾abstract¡¿  objective  to observe the effect of pharmacodynamics of kxlkl on chronic renal failure in experimental rats and investigate the mechanism of its improvement of glomerulosclerosis and renal interstitial fibrosis. methods  rats were randomly divided into control£¬model£¬kxlkl£¬da huang and dan shen(group) which were administrated for 30 days respectively. analysis of spss adopted£¬scr£¬bun£¬serum cholesterol£¬triglyceride were measured before and after treatment and observation of renal morphology. results  model group compared with kxlkl group£ºscr£¬bun£¬indexes were significantly decreased (p<0.05). compared to each treated group£ºscr£¬bun£¬indexes in kxlkl were significantly lower than that in dan shen and da huang. triglyceride in kxlkl was lower than that in model group (p<0.05). renal morphological structures were showed£ºglomerule atrophy of kxlkl in rats with chronic renal failure and multiple interstitial connective tissues were significantly mitigated£¬which were close to normal. conclusion kxlkl may have obvious effect of pharmacodyranics on improvement of experimental chronic renal failure.
   
    ¡¾key words¡¿  kang xian ling ke li£» animal experiment£» chronic renal failure£» renal interstitial fibrosis
   
    ÂýÐÔÉö¹¦ÄÜË¥½ß£¨chronic renal failure£¬crf£©ÊÇÁÙ´²³£¼ûµÄÎ£ÖØ²¡ÖÖÖ®Ò»¡£ËäÈ»ÉöÔಡѧÔÚ͸Îö¡¢ÒÆÖ²ºÍ·Ç͸ÎöÖÎÁƵȷ½ÃæÓкܴóµÄ ·¢Õ¹ £¬È»¶ø£¬crfÖÎÁÆÖл¹´æÔÚ²»ÉÙ ÎÊÌâ £¬ÈçcrfÔç¡¢ÖÐÆÚ·ÀÖÎÉв»µÃÁ¦£¬Í¸ÎöµÄ·ÇÉúÀíÐÔ£¬ÒÆÖ²ÅäÐÍ·½·¨µÄ²»ÍêÉÆ¼°¹©Éö²»×ãµÈ¡£ÔÚ¶àÄêÁÙ´²¾­ÑéµÄ»ù´¡ÉÏ£¬ÑÐÖÆ³ÉÁËÔÚ·öÕýìîа»ù´¡ÉÏ×ÅÖØ»îѪ»¯ðö¡¢ìîʪ×ǵĿ¹ÏËÁé·½¡£¾­ÁÙ´² Ñо¿ Ö¤Ã÷¿¹ÏËÁéÄÜÏÔÖø½µµÍcrf»¼Õߵļ¡ôû£¨scr£©¡¢ÄòËØµª£¨bun£©¼°µ¨¹Ì´¼£¨chl£©¡¢¸ÊÓÍÈýõ¥£¨tg£©£¬¸ÄÉÆÉö¹¦ÄܵÄ×÷Ó᣹ʿ¼ÂǽøÐж¯ÎïʵÑéÑо¿£¬ÒÔÃ÷È·ÆäÁÆÐ§ºÍ»úÖÆ¡£
   
    1  ²ÄÁÏÓë·½·¨
   
    1.1  ʵÑ鶯Îï  sdÐÛÐÔ´óÊó£¨180¡«200g£©ÓÉÉϺ£±Ø¿­ÖÐÐÄÌṩ¡£
   
    1.2  ʵÑé·½·¨  ´óÊó·ÖÁýËÇÑøÓÚÎÂÊÒ£¬12hÈÕÕÕ£¬45%ʪ¶ÈµÄ»·¾³ÖУ¬×ÔÓÉÒûË®£¬½øÊ³±ê×¼ÆÕͨËÇÁÏ¡£ÊÊÓ¦1ÖܺóÓÃplatt ·¨5/6ÉöÇгý×÷´óÊóÂýÐÔÉöË¥½ßÄ£ÐÍ£Û1£Ý£¬·ÖÁ½ÆÚÍê³É£¬Ïȱ³²¿ÇпÚÇгý×ó±Û2/3£¬·ìºÏºóÇгýÕû¸öÓÒÉö¡£¼ÙÊÖÊõ×é½ö±³²¿ÇпڷÖ2´Î°þÀë×óÓÒÉö°üĤ£¬±£ÁôÉöÉÏÏÙ¡£
   
    1.2.1  ¶¯Îï·Ö×éÉè¼Æ  ·ÖΪ5×飨¼ÙÊÖÊõ¶ÔÕÕ×é¡°a¡±4Ö»£¬Ä£ÐÍ×é¡°b¡±6Ö»£¬¿¹ÏËÁé×é¡°c¡±6Ö»£¬´ó»Æ×é¡°d¡±4Ö»£¬µ¤²Î×é¡°e¡±4Ö»£©£¬ÆäÖÐÔìÐÍ×é¡¢ÖÎÁÆ×é´óÊó¸ù¾ÝÊÖÊõºó2ÖÜËù²âѪ¼¡ôûÖµ·Ö×飬¾­Í³¼ÆÑ§´¦Àíʹ·Ö×éºó¸÷×éѪ¼¡ôû¡¢ÄòËØµªÖµÎÞÃ÷ÏÔ²îÒì¡£
   
    1.2.2  ÖÎÁÆ·½·¨  c×éÓ迹ÏËÁé·½£ºµ¤²Î15g£¬ÖÆ´ó»Æ12g£¬³´Å£Ï¥15g£¬ÌÒÈÊ12g£¬È«µ±¹é15g¡£d×éÓèÖÆ´ó»Æ12g¡£e×éÓ赤²Î15g¡£°´³ÉÈ˳£¹æÓÃÁ¿µÄ20±¶¸øÒ©¡£4×é´óÊó¾ù°´1.5ml/100gÌåÖØ½øÐйà裬a¡¢b×鏸ÓèµÈÁ¿ÉúÀíÑÎË®¡£c¡¢d¡¢e×é´óÊóÁ¬Ðø¹à·þ30Ì죨ʵÑéÖÐe×éÓÐÒ»ÊóËÀÍö£©£¬a¡¢b¡¢c¡¢d×é·Ö×°²¿·ÖѪÇåÓÚ-20¡æ±ùÏä±£´æÒÔ±¸¼à²â¡£È¡³öÉöÔ࣬¹Ì¶¨ÓÚ10%¸£¶ûÂíÁÖ»º³åÒºÖУ¬Ê¯À¯°üÂñ£¬ÇÐÆ¬£¬heºÍpasȾɫ¡£
   
    1.2.3  ¹Û²ìÖ¸±ê  ¼¡ôû£¨scr£©¡¢ÄòËØµª£¨bun£©¡¢µ¨¹Ì´¼£¨chl£©¡¢¸ÊÓÍÈýõ¥£¨tg£©¡¢Éö×éÖ¯½á¹¹¡£
   
    1.3  ͳ¼ÆÑ§·½·¨  ÊÔÑé½á¹ûÒÔspssÈí¼þ½øÐÐt¼ìÑ飬Éèp<0.05Ìáʾ¾ßÓÐͳ¼ÆÑ§ÒâÒå¡£
   
    2  ½á¹û
   
    2.1  ¿¹ÏËÁé¶Ôcrf´óÊóÉö¹¦ÄܵÄ×÷Óà ¼û±í1¡£

±í1  ¿¹ÏËÁé¶Ôcrf´óÊóѪ¼¡ôû¡¢ÄòËØµªµÄ×÷Óà £¨x¡Às£©

 

     ×¢£ºÖÎÁÆÇ°¸÷ÊÖÊõ×éÓë¼ÙÊÖÊõ×鼡ôû¡¢ÄòËØµª±È½Ï£¬*p<0.05£» ÊÖÊõ¸÷×éÖÎÁÆÇ°±È½Ï¼¡ôû¡¢ÄòËØµª£¬¡÷p<0.05£» ÖÎÁƺó¸÷ÖÎÁÆ×éÓëÄ£ÐͶÔÕÕ×éb±È½Ï£¬**p<0.05
   
    2.2  ¿¹ÏËÁé¶Ôcrf´óÊóѪ֬µÄ×÷Óà ¼û±í2¡£

±í2  ¿¹ÏËÁé¶Ôcrf´óÊóѪ֬µÄ×÷Óà £¨x¡Às£©

 

     ×¢£º¸÷ÊÖÊõ×éÓë¼ÙÊÖÊõ×éa×é±È½Ï£¬*p<0.05£» ¸÷ÖÎÁÆ×éÓë¶ÔÕÕ×éb×é±È½Ï£¬¡÷p<0.05£»µ¨¹Ì´¼c×éµÍÓÚb×飬µ«p>0.05ÎÞÃ÷ÏÔ²îÒ죻 d¡¢e×éÓëc×éÔÚÁ½ÏîÖ¸±ê±È½Ï£¬p>0.05£» ¸ÊÓÍÈýõ¥¿¹ÏËÁé×éd×éÓë¶ÔÕÕ×éb×é±È½Ï£¬¡÷p<0.05

¹²3Ò³: 1 [2] [3] ÏÂÒ»Ò³


³¤ÆÚ³£Äêµ¥²ÉѪ½¬ÕßÌåÄÚѪҺѧָ±êµÄÑо¿
Ó¦ÓÃö×ÊÔ¼ÁÄý½º·¨¼ì²é¿¹¿ñÈ®²¡ÑªÇåÖÐϸ¾úÄÚ¶¾ËصÄÑо¿
¹¤É̹ÜÀí | ¹¤¿ÆÂÛÎÄ | ²ÆÎñ¹ÜÀí | ¹ÜÀíѧ | ¹«¹²¹ÜÀí | ²ÆÕþ˰ÊÕ | ֤ȯ½ðÈÚ | »á¼ÆÉó¼Æ | ¼ÆËã»ú | ·¨ÂÉÂÛÎÄ | ҽҩѧ | ººÓïÑÔÎÄѧ
Éç»áÂÛÎÄ | ¹¤¿ÆÂÛÎÄ | Àí¿ÆÂÛÎÄ | ÎÄ»¯ÂÛÎÄ | ÒÕÊõÂÛÎÄ | ÎÄѧÂÛÎÄ | ÕÜѧÂÛÎÄ | ÕþÖÎÂÛÎÄ | Ó¢ÓïÂÛÎÄ | д×÷Ö¸µ¼ | ¼ÆËã»úÓ¦ÓÃ
www.zlunwen.com ÕÒÂÛÎÄÍø ® °æÈ¨ËùÓÐ ÍøÕ¾µØÍ¼